Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007

Recent advances in chronic lymphocytic leukemia (CLL) biology have produced a plethora of new prognostic tests, many of which are becoming available commercially. At the same time, advances in therapy have improved response rates and extended the survival of patients with CLL. In this review, we present our current interpretation of the most important CLL prognostic markers in the context of modern combination chemotherapy and outline our recommendations for their use in the clinic.